Theranostic Intratumoral Convection-Enhanced Delivery of124I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry
Open Access
- 14 August 2024
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 65 (9) , 1364-1370
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a rare childhood malignancy with poor prognosis. There are no effective treatment options other than external beam therapy. We conducted a pilot, first-in-human study using 124I-omburtamab imaging and theranostics as a therapeutic approach using a localized convection-enhanced delivery (CED) technique for administering radiolabeled antibody. We report the detailed pharmacokinetics and dosimetry results of intratumoral delivery of 124I-omburtamab. Methods: Forty-five DIPG patients who received 9.0–370.7 MBq of 124I-omburtamab intratumorally via CED underwent serial brain and whole-body PET/CT imaging at 3–5 time points after injection within 4, 24–48, 72–96, 120–144, and 168–240 h from the end of infusion. Serial blood samples were obtained for kinetic analysis. Whole-body, blood, lesion, and normal-tissue activities were measured, kinetic parameters (uptake and clearance half-life times) estimated, and radiation-absorbed doses calculated using the OLINDA software program. Results: All patients showed prominent activity within the lesion that was retained over several days and was detectable up to the last time point of imaging, with a mean 124I residence time in the lesion of 24.9 h and dose equivalent of 353 ± 181 mSv/MBq. Whole-body doses were low, with a dose equivalent of 0.69 ± 0.28 mSv/MBq. Systemic distribution and activities in normal organs and blood were low. Radiation dose to blood was very low, with a mean value of 0.27 ± 0.21 mGy/MBq. Whole-body clearance was monoexponential with a mean biologic half-life of 62.7 h and an effective half-life of 37.9 h. Blood clearance was biexponential, with a mean biologic half-life of 22.2 h for the rapid α phase and 155 h for the slower β phase. Conclusion: Intratumoral CED of 124I-omburtamab is a novel theranostics approach in DIPG. It allows for delivery of high radiation doses to the DIPG lesions, with high lesion activities and low systemic activities and high tumor–to–normal-tissue ratios and achieving a wide safety margin. Imaging of the actual therapeutic administration of 124I-omburtamab allows for direct estimation of the therapeutic lesion and normal-tissue–absorbed doses. Visual AbstractKeywords
This publication has 22 references indexed in Scilit:
- Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapyInternational Journal of Clinical Oncology, 2021
- Convection-enhanced delivery: chemosurgery in diffuse intrinsic pontine gliomaThe Lancet Oncology, 2018
- Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trialThe Lancet Oncology, 2018
- The potential of theragnostic 124I-8H9 convection-enhanced delivery in diffuse intrinsic pontine gliomaNeuro-Oncology, 2014
- Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem gliomaActa Neurochirurgica, 2013
- Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP‐16: A Children's Oncology Group phase II studyPediatric Blood & Cancer, 2007
- Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastomaAnnals of Neurology, 2003
- Intracranial Aneurysm and Vasculopathy after Surgery and Radiation Therapy for Craniopharyngioma: Case ReportNeurosurgery, 2002
- SAAM II: Simulation, analysis, and modeling software for tracer and pharmacokinetic studiesMetabolism, 1998
- High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumorsJournal of Neuro-Oncology, 1998